The Federal Circuit recently decided two appeals, Novartis AG v. Ezra Ventures LLC (“Ezra”) and Novartis Pharms. Corp. v. Breckenridge Pharm. Inc. (“Breckenridge”) that both relate to the effect of obviousness-type double...more
12/14/2018
/ Appeals ,
Double Patent ,
Life Sciences ,
Novartis ,
Obviousness ,
Obviousness-Type Double Patenting (ODP) ,
Patent Expiration ,
Patent Filings ,
Patent Infringement ,
Patent Invalidity ,
Patent Portfolios ,
Patent Term Adjustment ,
Patent Term Extensions ,
Patent Terms ,
Patents ,
Pharmaceutical Patents ,
Uruguay Round Agreements Act (URAA)
Over a century ago, in the famous Parke-Davis adrenaline patent infringement case, Judge Learned Hand articulated what many consider the origin of the legal premise that isolated components or purified extracts of natural...more